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Fragile X Syndrome is the most common inherited cause of autism. Fragile X mental retardation protein (FMRP),
which is absent in fragile X, is an mRNA binding protein that regulates the translation of hundreds of different
mRNA transcripts. In the adult brain, FMRP is expressed primarily in the neurons; however, it is also expressed
in developing glial cells, where its function is not well understood. Here, we show that fragile X (Fmr1) knockout
mice display abnormalities in the myelination of cerebellar axons as early as the first postnatal week, corre-
sponding roughly to the equivalent time in human brain development when symptoms of the syndrome first
become apparent (1–3 years of age). At postnatal day (PND) 7, diffusion tensor magnetic resonance imaging
showed reduced volume of the Fmr1 cerebellum compared with wild-type mice, concomitant with an 80–85%
reduction in the expression of myelin basic protein, fewer myelinated axons and reduced thickness of myelin
sheaths, as measured by electron microscopy. Both the expression of the proteoglycan NG2 and the number
of PDGFRa1 /NG21 oligodendrocyte precursor cells were reduced in the Fmr1 cerebellum at PND
7. Although myelin proteins were still depressed at PND 15, they regained wild-type levels by PND 30. These find-
ings suggest that impaired maturation or function of oligodendrocyte precursor cells induces delayed myelin-
ation in the Fmr1 mouse brain. Our results bolster an emerging recognition that white matter abnormalities in
early postnatal brain development represent an underlying neurological deficit in Fragile X syndrome.
INTRODUCTION
Fragile X Syndrome (FXS), the most common single gene cause
of autism, results from an expansion of a CGG repeat in the 5′ un-
translated region of the X-linked Fmr1 gene. The Fmr1 gene
codes for Fragile X Mental Retardation Protein (FMRP), an
mRNA binding protein that regulates the translation, stability
and transport of hundreds of mRNAs in the brain (1). Dys-
regulated protein synthesis is thought to result in many of the
biochemical and anatomical phenotypes associated with FXS
(2–4).
Human imaging and neuropathological studies have revealed
alterations in the cerebellum of persons with FXS that include a
reduction in the size of the vermis (5,6) and a loss of Purkinje
neurons (7). Both abnormalities have also consistently been
shown in individuals with idiopathic autism (8–10). In an MRI
analysis of the Fmr1 mouse (fragile X knockout mouse, an
animal model of the disorder) brain conducted at PND 30, the
most prominent change observed was a reduced volume and
loss of neurons in the deep cerebellar nuclei, which together
with the vestibular nuclei are the sole output of the cerebellar
cortex (11). Two separate studies have recently linked mutations
in the autism-associated genes TSC1 and TSC2 in Purkinje
neurons of the mouse cerebellum to several autism-like pheno-
types (12,13). Together, these findings suggest a role for the cere-
bellum in the pathology of autism spectrum disorders and FXS.
FMRP levels are high in the central nervous system where it is
widely and prominently expressed in adult neurons. FMRP is
also expressed in immature astrocytes (14,15) and oligodendro-
cytes (16), and glial expression of dFMRP is required for proper
neuroblast development in the drosophila model of FXS (17).
Although white matter abnormalities are well established in
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autism spectrum disorders and FXS (6,18–20), the effects of loss
of FMRP on cells of the oligodendrocyte lineage and on myelin
production have not been well studied.
The objective of this study was to examine oligodendrocyte
precursor cells (OPCs), oligodendroglia and myelin in the
Fmr1 mouse cerebellum throughout development. We report
reduced cerebellar volume accompanied by delayed myelination
and reduced OPC number over the first 2 weeks after birth. These
early postnatal abnormalities could underlie the delayed matur-
ation of neurons and contribute to neuronal dysfunction in the
adult FXS brain.
RESULTS
FMRP expression in the mouse cerebellum
In the mouse forebrain, FMRP expression has been shown to be
highest during early postnatal periods and to decrease as the
brain matures (21). To characterize the time course of FMRP ex-
pression in the mouse cerebellum, we examined FMRP expres-
sion in cerebellar homogenates from male wild-type C57BL/6
mice at various time points during the first 2 months of life
(Fig. 1A and B). FMRP expression was highest during the first
two postnatal weeks and began dropping by PND 21. Expression
leveled off at about 4 weeks after birth and remained steady
through to adulthood. The level of FMRP in the adult cerebellum
was50% of the peak level of expression attained between post-
natal weeks 1 and 2. The cellular distribution of FMRP in the
cerebellum was examined using immunocytochemistry. In the
cerebellar cortex, FMRP was expressed in all major neuronal
populations—granule cells, Purkinje cells and in interneurons
of the molecular layer at all timepoints examined (Fig. 1C).
FMRP was also highly expressed in neurons of the deep cerebel-
lar nuclei (data not shown). No FMRP expression was detected in
Fmr1 knockout mice (Fig. 1C).
FMRP staining was predominantly found in neurons;
however, in the deep cerebellar white matter of PND 7 wild-type
mice, 27+ 3.5% of cells expressing the OPC marker NG2
co-labeled with FMRP (Fig. 1D) while 27+ 2.3% of
PDGFRa expressing cells also expressed FMRP (Fig. 1E), sug-
gesting that as many as one-quarter of OPCs may express
FMRP in the wild-type cerebellum. The myelin marker myelin
basic protein (MBP) was also examined at PND 7. Although
anti-MBP labeled predominantly the myelin-rich processes of
oligodendrocytes, some oligodendrocyte cell bodies can be
identified using MBP immunostaining. In the deep cerebellar
white matter of wild-type PND 7 mice, 28+ 1.5% of MBP posi-
tive cell bodies co-labeled with FMRP (Fig. 1F), indicating that
FMRP expression can also be found in more mature oligoden-
drocytes in the cerebellum at PND 7. Together, these results
confirm the expression of FMRP in cells of the oligodendrocyte
lineage in the developing cerebellum.
Diffusion tensor imaging shows reduced volume
of the Fmr1 mouse cerebellum
Diffusion tensor imaging tracks the position and direction of
water molecules in tissues. It is particularly sensitive to myelin
and is often referred to as a white matter imaging technique
(22). Image registration revealed that PND 7 Fmr1 mice had a
significantly smaller cerebellar volume of 14.78 + 1.64 mm3
compared with the wild-type cerebellar volume of 18.40 +
1.66 mm3 (P ¼ 0.0001; Fig. 2A and B). Further analysis of rela-
tive brain volume (computed as a fraction of overall brain
volume) indicated that the cerebellum in the Fmr1 mice
remained small in relative volume (Fig. 2C; false discovery
rate ¼ 1%). No statistically significant differences between
wild-type and Fmr1 mice were seen in fractional anisotropy or
mean diffusion anywhere in the brains.
MBP and 2,3 cyclic nucleotide phosphodiesterase (CNPase)
expression display abnormal developmental profiles in the
Fmr1 cerebellum
To assess potential changes in oligodendrocytes and the status of
myelin, we used an antibody to MBP, a major protein component
of myelin (Fig. 3). Four isoforms of MBP, corresponding to 14,
17, 18.5 and 21.5 kDa, can be identified using western blotting.
The 17 and 18.5 kDa isoforms were difficult to distinguish sep-
arately and were therefore quantified together. Expression of
all MBP isoforms was dramatically lower in the Fmr1 cerebel-
lum at PND 7 compared with wild-type mice (Fig. 3A;
14 kDa: 16.1+ 1.8% of wild-type, P ¼ 0.02; 17/18.5 kDa:
14.0+ 5.1%, P ¼ 0.005; 21.5 kDa: 21.4+ 8.4%, P ¼ 0.03).
Immunocytochemical analysis of the PND 7 cerebellum con-
firmed the substantial under-expression of MBP (Fig. 3B). At
PND 15, a significant decrease was seen in the 14 and 17/
18.5 kDa bands (Fig. 3C; 14 kDa: 44.0+ 9.7%, P ¼ 0.04; 17/
18.5 kDa: 55.5+ 8.1%, P ¼ 0.04). Expression of the 21.5 kDa
band was not different between wild-type and Fmr1 (91.1+
14.2%, P ¼ 0.69). At PND 30, there was a non-significant de-
crease in the expression of all three MBP isoforms (Fig. 3D;
14 kDa 83+ 8.7% of wild-type, P ¼ 0.21; 17/18.5 kDa:
90.1+ 7.3, P ¼ 0.34; 21.5 kDa: 90.0+ 8.7%, P ¼ 0.40).
In contrast to the immature cerebellum, in the cerebellum of
2–4-month-old Fmr1 young adults, MBP expression was sig-
nificantly elevated compared with wild-type (Fig. 3E; 14 kDa:
133.9+ 8.0% of wild-type, P ¼ 0.02; 17/18.5 kDa: 134.5+
9.5%, P ¼ 0.03; 21.5 kDa: 132.4+ 6.7%, P ¼ 0.01). In older
adult mice 7–15 months old, MBP expression was not different
from wild-type (14 kDa: 114.8+ 9.6%, P ¼ 0.35; 17/18.5 kDa:
91.0+ 5.6%, P ¼ 0.47; 21.5 kDa: 87.7+ 7.6%, P ¼ 0.18;
blots not shown) suggesting that the elevation in early adulthood
is transient.These results are indicativeofdelayedmyelination in
the Fmr1 cerebellum, followed by transient over-compensation
in young adulthood.
To evaluate myelination over development in each genotype,
we directly compared the expression of MBP in samples from
PND 7, 15, 30, 2–4-month and 7–15-month-old wild-type
with Fmr1 mice using quantitative western blotting (Fig. 4).
For both genotypes, the expression of the three MBP isoforms
was low at PND 7, rose robustly by PND 15 and continued to
rise until at least PND 30. In both Fmr1 and wild-type mice ex-
pression of the different isoforms peaked at different develop-
mental timepoints; expression of the 21.5 kDa isoform peaked
at PND 30 then fell drastically in the adult, whereas the 17/
18.5 kDa forms plateaued around PND 30 while the 14 kDa
form continued to rise modestly into adulthood. Notably, over
the first 30 days of cerebellar development, all three isoforms
showed a general rightward shift in relative expression levels













in Fmr1 mice compared with wild-type mice. This finding is con-
sistent with a delay in myelination in the Fmr1 mouse.
Expression of a second myelin marker, CNPase, was also
examined in the cerebellum of young wild-type and Fmr1
animals (Fig. 5). At PND 7, CNPase expression was significantly
reduced in Fmr1 mice compared with wild-type (Fig. 5A;
24.0+ 1.0% of wild-type, P ¼ 0.04). At PND 15, there was a
non-significant decrease in CNPase in the Fmr1 cerebellum
(Fig. 5B; 86.6+ 10.0% of wild-type, P . 0.05). CNPase ex-
pression was not tested in older animals. These results are con-
sistent with a reduction in myelin in the Fmr1 cerebellum early
in development that appears to normalize as the brain matures.
Reduced myelination in the Fmr1 cerebellum
MBP expression is required for proper myelin formation (23)
and loss of MBP results in the absence of compact myelin and
the presence of thin myelin sheaths (24). Using electron micros-
copy, we examined the wild-type and Fmr1 cerebellum at PNDs
7 and 15 to look for structural changes in myelin formation that
could result from reduced MBP and CNPase expression (Fig. 6).
At PND 7, cerebellar white matter from Fmr1 mice contained
significantly fewer myelinated axons compared with matched
sections from wild-type mice (Fig. 6C; wild-type: 7.7+ 0.2
axons/100 mm2; Fmr1: 5.4+ 0.8 axons/100 mm2, P ¼ 0.04).
The average myelin thickness was also significantly reduced in
Fmr1 mice compared with wild-type (Fig. 6D; wild-type:
72.5+ 2.9 nm, Fmr1: 58.2+ 4.2 nm, P ¼ 0.013). Since the
myelin thickness varied widely between individual axons
within each mouse, the percentage of axons whose myelin thick-
ness fell within each of five bins was also calculated. This ana-
lysis showed a leftward shift in the distribution of myelin
thickness in Fmr1 mice, indicating the presence of fewer thick,
and more thin sheaths in Fmr1 compared with wild-type mice
(Fig. 6E). The G-ratio (diameter of the axon divided by diameter
of the axon plus myelin sheath) was also significantly higher in
Fmr1 cerebellum compared with wild-type, indicating a
thinner myelin sheath in Fmr1 animals (Fig. 6F; wild-type:
0.84+ 0.007, Fmr1: 0.87+ 0.001, P ¼ 0.02). At PND 7, axon
diameter was not different between wild-type and Fmr1
axons (Fig. 6G; WT: 1.23+ 0.04 mm, Fmr1: 1.20+ 0.05 mm,
P ¼ 0.43). At PND 15, there was no significant difference in
the number of myelinated axons (Fig. 6J), myelin thickness
(Fig. 6K), myelin thickness distribution (Fig. 6L), G-ratio
(Fig. 6M) or axon diameter (Fig. 6N) between wild-type and
Fmr1 mice. Taken together, these data demonstrate significantly
reduced myelination in Fmr1 knockout mice at PND 7.
OPCs are altered in young Fmr1 cerebellum
OPCs are characterized by the expression of NG2 chondroitin
sulfate and PDGFRa (25,26). To examine possible causes of
delayed myelination in Fmr1 cerebellum, the expression of
NG2 was examined via western blots. NG2 expression was sig-
nificantly reduced in the cerebellum of the Fmr1 mice at PND 7
(Fig. 7A; 68.0+ 8.4%, P , 0.05). In contrast, at PND 15, NG2
expression was elevated in Fmr1 mice (Fig. 7B; 162+ 28.4%,
P ¼ 0.05). NG2 expression declines rapidly with development
(27) and was not detectable by western blot in the wild-type or
Fmr1 cerebellum after PND 15. The observation that NG2 ex-
pression is reduced at PND 7 suggests a change in the number
or function of OPCs; this result is consistent with the very
large reductions in MBP and CNPase at this time point in
Fmr1 mice and could account for the delay in myelination.
To further examine the effect of loss of FMRP on OPCs, we
labeled cerebellar sections with antibodies to PDGFRa and
NG2 and counted the number of cells that expressed both
Figure 1. FMRP expression in the developing and mature wild-type mouse cere-
bellum. (A) Representative western blot of cerebellar FMRP expression during
postnatal development. (B) Mean FMRP expression at each timepoint (n¼ 2–4),
expressed relative to PND1. FMRPexpression is highestduring the first two post-
natal weeks, with expressiondecreasing to adult levels around PND 28.Error bars
represent standard error of the mean. (C) Immunofluorescence image of FMRP
expression in the cerebellar cortex of the adult wild-type mouse (top); no
FMRP expression was detected in the Fmr1cerebellum (bottom; scale bar ¼
50 mm). (D–F) At PND 7, FMRP co-localizes with a population of cells expres-
sing the OPC markers NG2 (D) and PDGFRa (E) in the cerebellar white matter of
wild-type mice. FMRP also co-localizes with some cells expressing the oligo-
dendrocyte marker MBP (F) at PND 7. Arrows indicate double-labeled cells.
Scale bar = 10mm for (D) and (E) and 20mM for (F). G, granular layer; P, Purkinje
cell layer; M, molecular layer.













markers at PND 7. At this age, the vast majority of double-
labeled cells were restricted to the deep white matter of the cere-
bellum, with relatively few cells found in the sub-cortical white
matter or the cerebellar cortex. In the PND 7 cerebellum, MBP
expression in wild-type (and Fmr1) mice was present predomin-
antly in the deep white matter, a finding consistent with previous
reports that myelination in the cerebellum is initiated in the deep
regions and proceeds outward (28). For these reasons, the
number of OPCs was counted only in the deep cerebellar white
matter. The number of cells double-labeled with PDGFRa and
NG2 was significantly reduced in Fmr1 cerebellum at PND 7
(Fig. 7C; wild-type: 3.9+ 0.28 cells/1000 mm2, Fmr1: 2.3+
0.5 cells/1000 mm2, P ¼ 0.04). This finding indicates a signifi-
cant reduction in the number of OPCs in deep white matter of
the Fmr1 cerebellum at PND 7. Given that the majority of
PDGFRa/NG2 cells and MBP expression were largely restricted
to this region at PND 7, it is reasonable to conclude that this re-
duction in OPC number could account for the reduced myelin-
ation observed in Fmr1 mice.
DISCUSSION
The present study demonstrates for the first time an abnormal
pattern of myelination in the Fmr1 mouse brain. We found that
the normal progression of myelination is delayed in the early
postnatal period in the Fmr1 mouse cerebellum, and that the
delay may be explained by a reduction in the number of OPCs
in the deep cerebellar white matter at this age. The observed ab-
normalities in the cerebellum become evident by the first post-
natal week, a time corresponding to approximately age 1–3
years in humans and the age at which most children with FXS
or autism are first diagnosed (29). Neuroimaging studies have
consistently demonstrated alterations in white matter volume
and structure in the brains of individuals with both FXS and
autism (18–20). Hoeft et al. (6) reported altered white matter
volume in several brain regions of 1–3-year-old boys with
FXS; this time frame is analogous to the postnatal period
where we observed reduced myelination in the Fmr1 mouse.
Reduced OPC number can cause delayed myelination
In the CNS, myelin is produced by oligodendrocytes, which
extend compacted spirals of membrane around multiple axons.
Developmentally, multipotent ventricular stem cells give rise
to committed OPCs, which proliferate to form the pool of cells
that eventually become mature oligodendrocytes. We found
that the deep cerebellar white matter of Fmr1 mice contained
40% fewer PDGFRa+/NG2+ cells compared with wild-type
mice. Reduced OPC number could contribute to the delayed
myelination observed during early postnatal development and
could reflect altered OPC survival or a delay in maturation or pro-
liferation.
NG2 is an important regulator of several signaling pathways,
including growth factor signaling through PDGFRa (27). The
expression of NG2 in the Fmr1 mouse cerebellum was signifi-
cantly reduced, and similar to the Fmr1 mouse, NG2 knockout
mice display delayed myelination which results from delayed
OPC proliferation and reduced oligodendrocyte number (26).
Although we did not measure proliferation rates in Fmr1 mice,
these findings in NG2 knockout mice suggest that diminished
OPC proliferation might also be a cause of fewer OPCs in
Fmr1 mice. OPC differentiation occurs when the number of
OPCs reaches a critical density (30). Therefore, reduced or
delayed OPC proliferation could impede OPC differentiation
resulting in the delayed myelination observed in Fmr1 mouse
cerebellum.
Proper myelination relies on bi-directional signaling between
oligodendrocytes and axons (31). Neuronal pathology is well
established in FXS but the present study raises the question of
whether delayed myelination reflects an axonal or glial deficit.
Axon diameter can regulate myelin thickness (32) and whether
an axon is myelinated (33). We saw no difference in axon diam-
eter in Fmr1 mice at PND 7 or 15 using electron microscopy. Ex-
pression of the axon-specific neurofilament-H was also not
different between Fmr1 and wild-type mice at PND 7 (data not
shown). These findings suggest the myelination defect is not
related to changes in axonal structure. The observation that
FMRP is expressed in OPCs and oligodendrocytes in wild-type
animals, and the deficiencies in OPC number and NG2 expres-
sion discussed earlier also suggest that the pathology in Fmr1
cerebellum is related, at least in part, to changes in the oligo-
dendrocyte lineage cells in the absence of FMRP.
Promising pharmacotherapies for FXS currently being
studied in the clinic include Group I metabotropic glutamate re-
ceptor (mGluR) antagonists and GABAB receptor agonists
(4,34,35). Interestingly, OPCs have been shown to express
both mGluR5 (36) and GABAB receptors (37) and the GABAB
receptor agonist R-baclofen was shown to increase OPC
Figure 2. Diffusion tensor imaging of the Fmr1 mouse cerebellum at PND 7. (A) A cross-sectional slice showing the cerebral structure visible with DTI. (B) The same
cross-section overlaid with a color scale-bar highlighting the regions which are statistically smaller in the Fmr1 mouse (in blue) compared with the wild-type controls.
Values correspond to the % false discovery rate (FDR). Note that the cerebellum (traced in red in A) is almost completely highlighted (false discovery rate, FDR, value
in %). (C) Quantification of cerebellar volume (in cubic mm; mean+SD; n ¼ 10 per genotype) demonstrates that the cerebellum of Fmr1 mice is significantly smaller
than that of wild-type mice at PND 7. ∗∗∗P , 0.001.













proliferation and differentiation in vitro (37). This suggests that,
in addition to correcting FXS-related phenotypes such as audio-
genic seizures and abnormal dendritic spine morphology
(38,39), early treatment with R-baclofen might also be beneficial
in treating the delayed myelination observed in Fmr1 mice.
RNA-binding proteins regulate the expression
of myelin proteins
Post-transcriptional regulation of myelin protein expression has
been shown to be a key regulatory mechanism in ensuring proper
myelin formation (40). The RNA-binding protein QKI regulates
the expression of several myelin associated proteins, including
MBP (41,42). Quaking mice, which have a mutation that
reduces QKI expression in oligodendocytes, have a deficit in
compact myelin that results in tremors in their hindquarters
during movement (43). These mice also have significantly
reduced expression of MBP which results from destabilization
and mis-localization of MBP mRNA in the cytoplasm of
oligodendrocytes (41).
Given the role of FMRP in regulating protein expression, it is
not surprising it is important for proper myelination. We have
demonstrated that OPCs and some oligodendrocytes express
FMRP in the PND 7 cerebellum. Wang et al. (16) reported that
OPCs, but not mature oligodendrocytes, express FMRP and
the decline in FMRP levels during maturation was correlated
with an increase in MBP expression. This group also demon-
strated that FMRP binds to and regulates the translation of
MBP mRNA in vitro. Using different experimental strategies,
several other groups have also identified the mRNAs for MBP
and CNPase (another myelin protein) as substrates for FMRP
(1,44). We observed a dramatic decrease in the protein expres-
sion of MBP and CNPase in young Fmr1 cerebellum, suggesting
Figure 3. MBP expression in the Fmr1 cerebellum. Quantitative western blotting
of wild-type and Fmr1 cerebellum revealed a significant decrease in the expres-
sion of MBP in Fmr1 mice at PND 7 (A) and PND 15 (B). Immunofluorescence
staining also demonstrated reduced MBP expression in the deep cerebellar white
matter at PND 7 (A). No significant differences in expression were evident at
PND 30 (C), but MBP expression .... Fmr1 cerebellum (D). In (A), DCN, deep
cerebellar nuclei; WM, white matter; scale bar ¼ 100 mm. n ¼ 4–16 per geno-
type. ∗P , 0.05; ∗∗P , 0.01.
Figure 4. MBP expression over development. Quantitative western blotting was
used to quantify the expression of the 21.5 kDa (A), 17.5/18.5 kDa (B) and
14 kDa (C) isoforms of MBP over development in wild-type (circle) and Fmr1
(squares with dotted line) cerebellum. Expression of MBP isoforms was quanti-
fied relative to expression in PND15 wild-type cerebellum. Fmr1 mice show a
rightward shift in MBP expression over development, suggesting a delay in mye-
lination in these mice relative to wild-type animals. n ¼ 4 per age per genotype.













that, in the absence of FMRP, inappropriate regulation of the ex-
pression of these (and potentially other, as yet unidentified pro-
teins) may result in the delayed myelination that we observed in
Fmr1 mice.
In addition to being an important component of myelin,
CNPase is also an RNA-binding protein that can regulate
mRNA translation (45), although its mRNA targets have not
yet been established. Therefore, in addition to indicating a reduc-
tion in mature myelin, under-expression of CNPase could also
have functional consequences in Fmr1 cerebellum owing to its
role in regulating protein translation.
Neuronal activity regulates myelination
Neuronal activity is an important regulator of myelination and it
is conceivable that altered neuronal activity could influence
myelination in FXS. OPCs can undergo depolarization in re-
sponse to neuronal activation (46). While the role of depolariza-
tion in OPCs is currently unclear, both proliferation and
differentiation of OPCs can be inhibited in vitro by treatment
with glutamate (47). This finding suggests that glutamate
signaling may limit myelination through its action on OPCs.
Neuronal hyperexcitability is well established in FXS
(15,29,38,48,49), although it is unclear how early in develop-
ment this hyperexcitability is established. It is possible that
early neuronal hyperexcitability could affect myelination,
thereby contributing to the abnormal neuronal structure and/or
function commonly seen later in development. However, the
profound deficit that we report here in myelin production in
the Fmr1 mouse cerebellum in the first 1–2 postnatal weeks is
in contrast to the relatively more subtle effects reported in
neurons at these early timepoints. For example, recent studies
have revealed somewhat mild changes in dendritic spines (50)
and cortical maturation (51) at PND 7 in Fmr1 mice. Therefore,
altered myelination might precede and possibly contribute to,
neuronal abnormalities. Further studies of neurons and oligoden-
drocytes are needed to determine the interplay between these two
cells types in FXS.
The importance of proper myelination during development
The timing of axonal myelination is critical for the normal devel-
opment of neurons (52). Of note is the observation of delayed
myelination in a maternal immune activation model of autism
where the offspring from female mice challenged with lipopoly-
saccharide during pregnancy showed a delay in myelination in
the immature brain that was normalized several weeks later, a
situation similar to what we report here in Fmr1 mice (53).
This group, and others who have used this model, report abnor-
mal behaviors that are thought to reflect autistic-like behaviors in
rodents, including altered motor activity, pre-pulse inhibition
and anxiety (54,55), suggesting a possible link between abnor-
mal myelin and many of the phenotypes common to autism
and FXS.
Few studies to date have addressed the importance of early
myelin/white matter deposition for the proper growth and devel-
opment of the human brain. Steele et al. (56) demonstrated the
importance of early white matter development in musicians.
Using diffusion tensor imaging to compare white matter organ-
ization between musicians who began training before age 7, and
those who began after age 7, the authors identified a ‘sensitive
period where experience produces long-lasting changes in the
brain and behaviour’ such that early musical training has differ-
ential impact on (increasing) white matter deposition and ‘sen-
sorimotor synchronization performance.’ This study and
others (e.g. 57,58) demonstrate a critical window for myelin de-
position that affects the structure and function of the brain well
into adulthood. By extension, it is possible that if myelin depos-
ition is reduced during this critical early postnatal period (as
documented here in the Fmr1 mouse brain), it could leave
lasting structural and behavioral deficits even as myelin levels
normalize.
CONCLUSIONS
Our results reveal a delay in myelination accompanied by
reduced OPC number and smaller cerebellar volume in Fmr1
mice during early postnatal development. The results reported
here, together with emerging evidence from imaging studies
conducted on humans with FXS and idiopathic autism, indicate
Figure 5. CNPase expression in the Fmr1 cerebellum. Quantitative western blot-
ting of WT and Fmr1 cerebellum revealed a significant decrease in the expression
of 2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNPase), a major component of
myelin, in Fmr1 mice at PND 7 (A). No significant differences in CNPase expres-
sion were detected at PND15 (B). n ¼ 4–8 per genotype. ∗P , 0.05.













that white matter abnormalities may represent a common early
disturbance in neurodevelopmental disorders. Although deteri-
oration of myelin is a hallmark of multiple sclerosis and other de-
myelinating disorders affecting adolescents and adults, the
consequences of delayed myelination during brain development
are less well understood (52,58). Further investigations into the
role of FMRP in OPCs, and the dynamic relationship between
delayed myelination and FXS-related neuronal abnormalities
have the potential to lead to a better understanding of the under-
lying neuropathology of FXS.
MATERIALS AND METHODS
Animals
All animal experiments were carried out in accordance with the
guidelines set out by the Canadian Council on Animal Care and
were approvedby the UniversityofTorontoAnimalCareCommit-
tee. Wild-type C57BL/6 and Fmr1 knockout mice (backcrossed
.10 generations on the C57BL/6 background) were generously
provided by Dr William Greenough, University of Illinois, and
bred at the University of Toronto. All mice were the off-spring
Figure 6. Electron microscopy of PND 7 and PND 15 cerebellar axons. (A and H) Photomicrographs of wild-type and Fmr1 knockout cerebellum showing fewer
myelinated axons in Fmr1 cerebellum at PND 7 (A) but not PND15 (H) compared with wild-type. (B and I) Higher magnification images of wild-type and Fmr1 knock-
out showing a reduction in myelin thickness in Fmr1 axons at PND 7 (B) but no difference at PND15 (I). (C–G) Histograms showing significantly fewer myelinated
axons (C), reduced myelin thickness (D), an altered distribution of myelin thicknesses (E), increased G-ratio (F) and no difference in axon diameter (G) in Fmr1 knock-
out mice compared with wild-type at PND 7. No significant differences in these parameters were seen at PND 15 (J–N). n ¼ 2–3 per genotype. Scale bars in (A) and
(F) ¼ 2 mm; scale bars in (B) and (G) ¼ 500 nm. ∗P , 0.05; ∗∗P , 0.01.













of homozygous pairings. Animals were gender-matched within
each experiment and the data presented represents a combination
of results from matched male and female mice.
Immunocytochemistry
PND 15, 30 or adult (2–4 months) wild-type and Fmr1 knockout
mice were anaesthetized with ketamine/xylazine and intracar-
dially perfused with 0.1M PBS followed by 4% paraformalde-
hyde. Brains were removed and post-fixed overnight in 4% PFA
at 48C. Brains were subsequently rinsed with PBS and sunk in
30% sucrose/PBS overnight at 48C. The cerebellum was
removed, embedded in OCT and sectioned with a cryostat. Float-
ing coronal cerebellar sections (25 mm) were rinsed in PBS then
blocked for 1 h at room temperature in PBS containing 5% goat
serum and 0.2% triton X-100. After three 5 min washes, sections
were incubated in primary antibody overnight at 48C. Sections
werewashed 5 × 10 min inPBS then incubated insecondaryanti-
body for 2 h at room temperature. After 5 × 10 min washes, sec-
tions were mounted on glass slides with Prolong Gold Antifade
(Invitrogen). For NG2/PDGFRa double labeling, perfused PND
7 brains were placed directly in 30% sucrose (no post-fix) over-
night and 14 mm frozen sections were mounted on Superfrostw
(VWR) slides and treated as described earlier.
For sections treated with the 2F5 anti-FMRP antibody, antigen
retrieval was performed as described by Gabel et al. (59). Briefly,
floating sections were treated with 0.8% sodium borohydride,
washed with PBS then incubated for 45 min at 758C in 0.01 M
Na citrate, pH 6.0. After cooling to room temperature, sections
were rinsed with PBS, blocked and treated with primary and sec-
ondary antibodies as described earlier.
All primary and secondary antibodies were diluted in 0.1 M
PBS containing 5% goat serum. Primary antibodies included
rat-anti MBP (1:1000, Millipore); rat -anti PDGFRa (1:100,
BD Pharmigen); rabbit anti-NG2 (1:250; Millipore); mouse
monoclonal anti-FMRP (clone 2F5-1, 1:1000, gift of Dr
J. Darnell). Secondary antibodies were goat anti-mouse Alexa-
Fluor 488 (1:2000); goat anti-rabbit AlexaFluor 594 (1:1000);
anti-rat AlexaFluor 488 (1:500).
For co-localization of PDGFRa and NG2, digital images of
the deep white matter of the cerebellum (Fig. 7D) were captured
using a Nikon A1R Confocal Laser Microscope System driven
by the Nikon Elements software package. The analysed sections
corresponded approximately to the region between the coordi-
nates 28.79 mm bregma and 29.03 mm bregma according to
Paxinos et al. (60). Images were processed using Image J soft-
ware (NIH) and the number of cells in the deep cerebellar
white matter expressing both NG2 and PDGFRa was counted
and expressed as the number of cells per 1000 mm2. A total of
three wild-type and three Fmr1 knockout brains were analyzed
in pairs and 4–8 separate matched images were analyzed from
each pair. An unpaired Student’s t-test was used to determine
statistical significance.
For FMRP co-localization with MBP, NG2 and PDGFRa,
14 mm thaw-mounted cryostat sections from PND 7 wild-type
mice were treated as outlined earlier. Digital images of the deep
white matter (Fig. 7D) from 4–8 sections per mouse were cap-
tured as above and the number of cell bodies co-labeled with
FMRP and MBP or NG2 or PDGFR were counted and expressed
as a percent of all cell bodies expressing the MBP or NG2 or
PDGFRa. n ¼ 4 for MBP and NG2 and n ¼ 3 for PDGFRa.
Electron microscopy
PND 7 and 15 wild-type and Fmr1 mice were anesthetized with
ketamine/xylazine and intra-cardially perfused with 0.1 M PBS
Figure 7. OPCs in the young mouse cerebellum. Western blots of whole cerebellum using an antibody to the oligodendrocyte precursor cell (OPC) marker NG2
demonstrated a reduction in NG2 expression in the cerebellum of Fmr1 knockout mice at PND 7 compared with wild-type (A). In contrast, at PND 15, NG2 expression
was elevated in the Fmr1 cerebellum (B). NG2 expression was below the level of detection in the samples of cerebellum from PND 30 and adult wild-type and Fmr1
mice. (C) Immunocytochemical analysis revealed that the number of OPCs double labeled for NG2 and PDGFRawas significantly reduced in Fmr1 knockout mice at
PND 7 compared with wild-type. (D) Schematic diagram showing the location of the deep white matter from which OPC numbers were quantified. (E) Representative
images of NG2/PDGFRa staining in PND 7 cerebellum. n ¼ 8 per genotype for western blot; n ¼ 3 per genotype for immunocytochemistry. ∗P , 0.05.













followed by 4% paraformaldehyde plus 1% glutaradehyde (in
0.1 M PBS, pH7.2). The cerebellum was dissected and post-fixed
in paraformaldehyde plus glutaraldehyde at room temperature
for 2 h after which the fixative was removed and replaced with
fresh fixative and the samples were stored at 48C. After
washing, the samples were post-fixed with 1% osmium tetraox-
ide in PBS for 2 h at room temperature in the dark. The samples
were washed with PBS followed by dehydration using a graded
series of ethanol/distilled water: 50, 70, 90 and 100% in 45 min,
45 min, 1 h and 2 h, respectively at room temperature. The
samples were then washed with propylene oxide and infiltrated
with Spurrs resin using a graded series of Spurrs and Propylene
oxide mixture: (i) one part Spurrs resin mixed with two parts
100% PO for 2 h using an agitator; (ii) two parts Spurrs resin
mixed with one part 100% PO for 3 h using an agitator; (iii)
100% Spurrs overnight using an agitator; (iv) second change
with 100% Spurrs resin after the overnight for 2 h. Samples
were placed in the mold and polymerized at 608C for 48 h.
After complete polymerization, the sample was sectioned on a
Reichert Ultracut E microtome to 90 nm thickness and collected
on 200 mesh copper grids. The sections were stained using satu-
rated uranyl acetate for 15 min, rinsed in distilled water, fol-
lowed by Reynold’s lead citrate. The sections were examined
and the deep cerebellar white matter was photographed in a
Hitachi H7000 transmission electron microscope at an accelerat-
ing voltage of 75 kV. Images were analyzed using Image J soft-
ware. For each animal, the number of myelinated neurons were
counted in each of 12–14 low magnification images and the
average density was calculated (total area per image was
697 mm2). Using Image J software, myelin thickness was mea-
sured for .200 axons from 10 images per mouse. The data
were pooled to produce a mean myelin thickness for each
animal, or binned to provide an analysis of distribution of
myelin thickness.
Whole fiber (axon plus myelin) and axonal areas were mea-
sured for .140 axons from six images and used to derive
axonal and whole fiber diameters as described previously (61).
Longitudinally sectioned fibers were excluded from this ana-
lysis. The G ratio, a measure of myelin thickness, was calculated
as axonal diameter/whole fiber diameter.
Diffusion tensor imaging
PND 7 wild-type and Fmr1 mice (n ¼ 10 per genotype) were
intra-cardially perfused with PBS containing 1 ml/ml heparin
with 2 mM gadolinium DTPA (ProHance), followed by 4% par-
aformaldehyde containing 2 mM gadolinium. Skulls were iso-
lated and fixed overnight in 4% paraformaldehyde with 2 mM
gadolinium at 48C. The brains were then kept in PBS with
2 mM gadolinium and 0.02% sodium azide until imaged.
Imaging was conducted with Diffusion Tensor Imaging having
a resolution of 78 mm and 30 different directions. The high-b
images (b ¼ 1917 s/mm2) of all 20 brains were registered by
first aligning them in 3-D space to create a consensus average
brain. Here the high-b images were used because they offered
an increased contrast between the white and grey matter that
was not visible in the low-B images. Next, deformation fields
that transform each individual brain image to this consensus
average image were computed. These deformation fields were
utilized in calculating voxel-wise volumetric brain changes.
Volumetric changes of the cerebellum were extracted by
tracing in 3D space and computing the 3D volume. After acqui-
sition, the images were analyzed using FSL software package
(FMRIB, Oxford, UK), which was used to create Fractional
Anisotropy maps for each of the 20 brains imaged.
Western blotting
Quantitative western blotting was performed as previously
described (62). The cerebellum was isolated and homogenized in
ice cold 50 mM Tris–HCl, 1% SDS, pH 7.4, supplemented with
protease inhibitor cocktail (Roche) using a glass/teflon homogen-
izer. Protein concentrations were determined using the BCA assay
(Sigma). Equal amounts of protein (6–30 mg depending on the
abundance of the target protein) were loaded onto a 6, 10 or 12%
polyacrylamide–SDS gel and transferred onto a nitrocellulose
membrane after electrophoresis. The membranes were blocked
in 5% milk for 1 h and incubated at 48C overnight with one of
the following primary antibodies: rat anti-MBP (1:1000; Milli-
pore), rabbit anti-NG2 (1:250; Millipore) or mouse anti-CNPase
(1: 500, Millipore) and mouse anti-GAPDH antibody (1:40
000–1:100 000; Sigma). After washing, a goat anti-mouse, goat
anti-rabbit or goat anti-rat (Jackson Labs) HRP-conjugated sec-
ondary antibody was applied for 2 h. The immunoreactive proteins
were visualized using the FluorChemTM MultiImage Light
Cabinet (Alpha Innotech). Densitometric analysis was carried
out using the AlphaEaseFC software (Alpha Innotech). The inten-
sity of the band of interest was normalized relative to the GAPDH
band intensity. Protein expression in WT and Fmr1 knockout
animals is presented as a percentage of wild-type expression
levels. An unpaired Student’s t-test was performed to determine
statistical significance.
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